Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiration, Artificial | 16 | 2014 | 358 | 2.880 |
Why?
|
Pemphigus | 6 | 2021 | 14 | 2.800 |
Why?
|
Intensive Care Units | 16 | 2014 | 398 | 2.650 |
Why?
|
Critical Illness | 14 | 2014 | 311 | 2.570 |
Why?
|
Muscle Weakness | 6 | 2014 | 61 | 1.940 |
Why?
|
Polyneuropathies | 4 | 2014 | 27 | 1.520 |
Why?
|
Critical Care | 12 | 2014 | 384 | 1.490 |
Why?
|
Immunoglobulin G | 4 | 2021 | 469 | 1.360 |
Why?
|
Conscious Sedation | 7 | 2014 | 69 | 0.980 |
Why?
|
Autoantibodies | 4 | 2021 | 270 | 0.950 |
Why?
|
Muscle Relaxants, Central | 2 | 2013 | 10 | 0.900 |
Why?
|
Neuromuscular Blockade | 2 | 2013 | 26 | 0.880 |
Why?
|
Length of Stay | 7 | 2014 | 749 | 0.840 |
Why?
|
Desmoglein 3 | 2 | 2020 | 5 | 0.840 |
Why?
|
Desmoglein 1 | 2 | 2020 | 7 | 0.840 |
Why?
|
Hypnotics and Sedatives | 5 | 2014 | 132 | 0.810 |
Why?
|
Receptors, Fc | 2 | 2021 | 32 | 0.760 |
Why?
|
Patient Transfer | 3 | 2012 | 99 | 0.740 |
Why?
|
Receptor, Muscarinic M3 | 1 | 2020 | 12 | 0.710 |
Why?
|
Prednisone | 3 | 2020 | 255 | 0.670 |
Why?
|
Receptors, Nicotinic | 1 | 2020 | 131 | 0.650 |
Why?
|
Thoracic Diseases | 2 | 2014 | 27 | 0.530 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 3 | 2024 | 6 | 0.500 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2021 | 952 | 0.500 |
Why?
|
Humans | 65 | 2024 | 90014 | 0.500 |
Why?
|
Skin | 5 | 2020 | 589 | 0.480 |
Why?
|
Benzodiazepines | 2 | 2012 | 69 | 0.470 |
Why?
|
Infliximab | 1 | 2015 | 159 | 0.460 |
Why?
|
Dermatologic Agents | 1 | 2015 | 73 | 0.450 |
Why?
|
Pulmonary Medicine | 1 | 2014 | 46 | 0.450 |
Why?
|
Interactive Ventilatory Support | 1 | 2013 | 5 | 0.450 |
Why?
|
Inpatients | 2 | 2016 | 312 | 0.440 |
Why?
|
Delirium | 3 | 2014 | 72 | 0.440 |
Why?
|
Hospital Mortality | 4 | 2015 | 408 | 0.440 |
Why?
|
Respiratory Rate | 1 | 2013 | 20 | 0.440 |
Why?
|
Ventilator-Induced Lung Injury | 1 | 2013 | 31 | 0.440 |
Why?
|
Deep Sedation | 1 | 2013 | 15 | 0.440 |
Why?
|
Life Support Care | 2 | 2012 | 50 | 0.430 |
Why?
|
Analgesia | 1 | 2013 | 58 | 0.420 |
Why?
|
Practice Patterns, Physicians' | 3 | 2013 | 608 | 0.420 |
Why?
|
Middle Aged | 36 | 2024 | 26173 | 0.410 |
Why?
|
Hospitals, Chronic Disease | 1 | 2012 | 2 | 0.400 |
Why?
|
Aged | 32 | 2024 | 19272 | 0.400 |
Why?
|
Intermediate Care Facilities | 1 | 2011 | 2 | 0.390 |
Why?
|
Health Services Research | 2 | 2012 | 138 | 0.380 |
Why?
|
Male | 40 | 2024 | 42705 | 0.370 |
Why?
|
Skilled Nursing Facilities | 1 | 2011 | 43 | 0.370 |
Why?
|
Physical Therapy Modalities | 4 | 2014 | 84 | 0.370 |
Why?
|
Female | 39 | 2024 | 46617 | 0.360 |
Why?
|
Practice Guidelines as Topic | 4 | 2014 | 1055 | 0.360 |
Why?
|
Shock, Septic | 2 | 2013 | 105 | 0.350 |
Why?
|
Analgesics, Opioid | 2 | 2012 | 451 | 0.350 |
Why?
|
Biomedical Research | 2 | 2012 | 405 | 0.350 |
Why?
|
Adult | 28 | 2024 | 26836 | 0.340 |
Why?
|
Multiple Organ Failure | 1 | 2010 | 55 | 0.340 |
Why?
|
Neuromuscular Blocking Agents | 1 | 2009 | 28 | 0.330 |
Why?
|
Recovery of Function | 1 | 2011 | 301 | 0.330 |
Why?
|
Medical Staff, Hospital | 1 | 2010 | 109 | 0.330 |
Why?
|
Risk Factors | 10 | 2024 | 5562 | 0.330 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2010 | 96 | 0.320 |
Why?
|
Rituximab | 2 | 2020 | 117 | 0.320 |
Why?
|
Tidal Volume | 1 | 2008 | 54 | 0.320 |
Why?
|
Inhalation | 1 | 2008 | 31 | 0.310 |
Why?
|
Analgesics | 1 | 2009 | 119 | 0.310 |
Why?
|
Patient Discharge | 1 | 2011 | 326 | 0.310 |
Why?
|
Hysterectomy | 1 | 2009 | 156 | 0.300 |
Why?
|
Extravascular Lung Water | 1 | 2008 | 5 | 0.300 |
Why?
|
Physician Executives | 1 | 2008 | 23 | 0.300 |
Why?
|
Societies, Medical | 1 | 2012 | 584 | 0.300 |
Why?
|
Lymph Node Excision | 1 | 2009 | 220 | 0.290 |
Why?
|
Dermatitis Herpetiformis | 3 | 2006 | 9 | 0.290 |
Why?
|
Patient Admission | 1 | 2008 | 114 | 0.290 |
Why?
|
Young Adult | 8 | 2021 | 6418 | 0.280 |
Why?
|
Adrenal Insufficiency | 1 | 2006 | 23 | 0.280 |
Why?
|
Muscular Diseases | 1 | 2007 | 64 | 0.280 |
Why?
|
E-Selectin | 1 | 2006 | 30 | 0.270 |
Why?
|
Academic Medical Centers | 2 | 2010 | 385 | 0.260 |
Why?
|
Interleukin-8 | 1 | 2006 | 86 | 0.260 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2009 | 296 | 0.260 |
Why?
|
Occupational Therapy | 3 | 2010 | 16 | 0.260 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2006 | 700 | 0.250 |
Why?
|
Early Ambulation | 3 | 2010 | 25 | 0.250 |
Why?
|
Myocardial Ischemia | 1 | 2007 | 164 | 0.250 |
Why?
|
Brain Diseases | 1 | 2006 | 186 | 0.230 |
Why?
|
Drug Therapy, Combination | 3 | 2015 | 785 | 0.230 |
Why?
|
Heart Arrest | 3 | 2012 | 278 | 0.230 |
Why?
|
Retrospective Studies | 13 | 2024 | 9237 | 0.220 |
Why?
|
Endothelial Cells | 1 | 2006 | 464 | 0.210 |
Why?
|
Respiratory Insufficiency | 3 | 2010 | 162 | 0.210 |
Why?
|
Pemphigoid, Bullous | 2 | 1999 | 12 | 0.200 |
Why?
|
Treatment Outcome | 9 | 2024 | 8292 | 0.200 |
Why?
|
Autoantigens | 2 | 2020 | 129 | 0.200 |
Why?
|
Coronary Artery Disease | 1 | 2007 | 367 | 0.200 |
Why?
|
Bed Rest | 3 | 2010 | 5 | 0.190 |
Why?
|
Vital Signs | 2 | 2012 | 37 | 0.190 |
Why?
|
Scleroderma, Localized | 1 | 2020 | 9 | 0.180 |
Why?
|
Iron-Binding Proteins | 1 | 2020 | 15 | 0.180 |
Why?
|
Propofol | 2 | 2014 | 92 | 0.180 |
Why?
|
Scleroderma, Systemic | 1 | 2020 | 53 | 0.170 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 201 | 0.170 |
Why?
|
Elasticity Imaging Techniques | 1 | 2020 | 57 | 0.170 |
Why?
|
Survivors | 2 | 2011 | 234 | 0.170 |
Why?
|
Immunosuppressive Agents | 1 | 2024 | 979 | 0.160 |
Why?
|
Iodide Peroxidase | 1 | 2020 | 206 | 0.150 |
Why?
|
Logistic Models | 5 | 2014 | 1214 | 0.150 |
Why?
|
Sepsis | 2 | 2014 | 329 | 0.150 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 358 | 0.150 |
Why?
|
Guideline Adherence | 2 | 2011 | 234 | 0.150 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2017 | 10 | 0.150 |
Why?
|
Chronic Disease | 1 | 2021 | 958 | 0.150 |
Why?
|
Conjunctival Diseases | 1 | 2017 | 7 | 0.150 |
Why?
|
Spectrum Analysis | 1 | 2018 | 119 | 0.150 |
Why?
|
Conjunctiva | 1 | 2017 | 19 | 0.150 |
Why?
|
Carcinoma, Basal Cell | 1 | 2018 | 63 | 0.140 |
Why?
|
Adjuvants, Immunologic | 1 | 2018 | 169 | 0.140 |
Why?
|
Optical Imaging | 1 | 2018 | 51 | 0.140 |
Why?
|
Cohort Studies | 4 | 2014 | 2887 | 0.140 |
Why?
|
Adolescent | 6 | 2021 | 9347 | 0.140 |
Why?
|
United States | 5 | 2016 | 7114 | 0.130 |
Why?
|
Dermatomycoses | 1 | 2015 | 9 | 0.130 |
Why?
|
Case-Control Studies | 5 | 2018 | 1868 | 0.130 |
Why?
|
Aged, 80 and over | 8 | 2024 | 6787 | 0.130 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 153 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2018 | 598 | 0.130 |
Why?
|
Hospitalization | 3 | 2016 | 888 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2015 | 60 | 0.130 |
Why?
|
Severity of Illness Index | 3 | 2020 | 1863 | 0.130 |
Why?
|
Cytokines | 1 | 1999 | 811 | 0.120 |
Why?
|
Wakefulness | 2 | 2012 | 135 | 0.120 |
Why?
|
Immobilization | 1 | 2014 | 21 | 0.120 |
Why?
|
Health Care Costs | 1 | 2016 | 236 | 0.110 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2014 | 50 | 0.110 |
Why?
|
Canada | 1 | 2014 | 208 | 0.110 |
Why?
|
Immune System Diseases | 1 | 2014 | 27 | 0.110 |
Why?
|
Fentanyl | 1 | 2014 | 71 | 0.110 |
Why?
|
Confidence Intervals | 2 | 2011 | 221 | 0.110 |
Why?
|
History, 21st Century | 1 | 2014 | 185 | 0.110 |
Why?
|
Predictive Value of Tests | 4 | 2018 | 1732 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2014 | 172 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 140 | 0.110 |
Why?
|
Dermatology | 3 | 2003 | 40 | 0.110 |
Why?
|
Bacteremia | 1 | 2014 | 103 | 0.110 |
Why?
|
Vasopressins | 1 | 2013 | 50 | 0.110 |
Why?
|
History, 20th Century | 1 | 2014 | 315 | 0.100 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 56 | 0.100 |
Why?
|
Norepinephrine | 1 | 2013 | 172 | 0.100 |
Why?
|
Remote Consultation | 2 | 2003 | 16 | 0.100 |
Why?
|
Prognosis | 3 | 2014 | 3800 | 0.100 |
Why?
|
Regression Analysis | 1 | 2013 | 591 | 0.100 |
Why?
|
Prospective Studies | 5 | 2018 | 4329 | 0.100 |
Why?
|
Withholding Treatment | 1 | 2012 | 116 | 0.100 |
Why?
|
Triage | 1 | 2012 | 117 | 0.090 |
Why?
|
Work | 1 | 2011 | 15 | 0.090 |
Why?
|
Staphylococcal Infections | 1 | 2014 | 272 | 0.090 |
Why?
|
Catheterization, Central Venous | 2 | 2009 | 114 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 1098 | 0.090 |
Why?
|
Time Factors | 5 | 2012 | 5361 | 0.090 |
Why?
|
Staphylococcus aureus | 1 | 2014 | 278 | 0.090 |
Why?
|
After-Hours Care | 1 | 2010 | 8 | 0.090 |
Why?
|
Night Care | 1 | 2010 | 9 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 344 | 0.090 |
Why?
|
Convalescence | 1 | 2010 | 12 | 0.090 |
Why?
|
Pneumonia | 1 | 2011 | 183 | 0.090 |
Why?
|
Anniversaries and Special Events | 1 | 2010 | 15 | 0.090 |
Why?
|
Neurologic Examination | 1 | 2010 | 120 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 3684 | 0.080 |
Why?
|
Circadian Rhythm | 1 | 2012 | 303 | 0.080 |
Why?
|
Chicago | 2 | 2011 | 1434 | 0.080 |
Why?
|
Glucocorticoids | 2 | 2024 | 358 | 0.080 |
Why?
|
Survival Analysis | 2 | 2014 | 1497 | 0.080 |
Why?
|
Insulin Resistance | 2 | 2014 | 353 | 0.080 |
Why?
|
Exercise Therapy | 1 | 2009 | 82 | 0.080 |
Why?
|
Animals | 3 | 2013 | 27536 | 0.080 |
Why?
|
Ventilators, Mechanical | 1 | 2008 | 35 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2010 | 225 | 0.080 |
Why?
|
Neck | 1 | 2009 | 104 | 0.080 |
Why?
|
Cross-Sectional Studies | 2 | 2012 | 1731 | 0.080 |
Why?
|
Sleep | 1 | 2012 | 455 | 0.080 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 53 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 435 | 0.070 |
Why?
|
Pulmonary Edema | 1 | 2008 | 50 | 0.070 |
Why?
|
Periodicals as Topic | 1 | 2010 | 168 | 0.070 |
Why?
|
ROC Curve | 4 | 2012 | 778 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2009 | 210 | 0.070 |
Why?
|
Attitude of Health Personnel | 1 | 2012 | 654 | 0.070 |
Why?
|
Movement | 1 | 2009 | 313 | 0.070 |
Why?
|
Lymphatic Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2008 | 281 | 0.070 |
Why?
|
RNA, Messenger | 2 | 2006 | 2026 | 0.070 |
Why?
|
Butyrophenones | 1 | 2006 | 5 | 0.070 |
Why?
|
Central Venous Pressure | 1 | 2006 | 26 | 0.070 |
Why?
|
Thoracotomy | 1 | 2007 | 64 | 0.070 |
Why?
|
Immunoglobulin A | 2 | 2006 | 83 | 0.070 |
Why?
|
L-Selectin | 1 | 2006 | 16 | 0.070 |
Why?
|
Biopsy, Needle | 1 | 2007 | 231 | 0.070 |
Why?
|
Jugular Veins | 1 | 2006 | 74 | 0.070 |
Why?
|
Body Weight | 1 | 2008 | 453 | 0.070 |
Why?
|
Decision Making | 2 | 2012 | 671 | 0.070 |
Why?
|
Hypercapnia | 1 | 2006 | 44 | 0.070 |
Why?
|
Endosonography | 1 | 2007 | 99 | 0.070 |
Why?
|
Transglutaminases | 1 | 2006 | 40 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2006 | 74 | 0.070 |
Why?
|
Gastroenteritis | 1 | 2006 | 26 | 0.070 |
Why?
|
Robotics | 1 | 2009 | 270 | 0.070 |
Why?
|
Biomarkers | 2 | 2006 | 1778 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2014 | 848 | 0.060 |
Why?
|
GTP-Binding Proteins | 1 | 2006 | 145 | 0.060 |
Why?
|
Physical Examination | 1 | 2006 | 150 | 0.060 |
Why?
|
Interleukin-1 | 1 | 2005 | 72 | 0.060 |
Why?
|
Coma | 1 | 2006 | 47 | 0.060 |
Why?
|
Physicians | 1 | 2012 | 692 | 0.060 |
Why?
|
Risk Assessment | 1 | 2012 | 2327 | 0.060 |
Why?
|
Monocytes | 1 | 2005 | 221 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2005 | 264 | 0.060 |
Why?
|
Lung | 1 | 2011 | 1292 | 0.060 |
Why?
|
Pain | 1 | 2006 | 400 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2007 | 550 | 0.050 |
Why?
|
Affect | 1 | 2005 | 389 | 0.050 |
Why?
|
Visual Acuity | 1 | 2024 | 199 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2006 | 841 | 0.050 |
Why?
|
Prevalence | 1 | 2007 | 1250 | 0.050 |
Why?
|
Dapsone | 1 | 1982 | 10 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2010 | 2395 | 0.050 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 1982 | 18 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2005 | 322 | 0.050 |
Why?
|
Quality of Life | 1 | 2011 | 1682 | 0.050 |
Why?
|
Laparoscopy | 1 | 2009 | 780 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2002 | 40 | 0.050 |
Why?
|
Single-Blind Method | 2 | 2014 | 151 | 0.050 |
Why?
|
Recurrence | 1 | 2024 | 1147 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1982 | 212 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 305 | 0.040 |
Why?
|
Healthy Volunteers | 1 | 2020 | 146 | 0.040 |
Why?
|
Electrocardiography | 2 | 2012 | 497 | 0.040 |
Why?
|
Disease Progression | 1 | 2024 | 1469 | 0.040 |
Why?
|
Interleukin-5 | 1 | 1999 | 36 | 0.040 |
Why?
|
Child | 3 | 2006 | 7242 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 1999 | 56 | 0.040 |
Why?
|
Interleukin-13 | 1 | 1999 | 38 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2002 | 345 | 0.040 |
Why?
|
Interleukin-4 | 1 | 1999 | 129 | 0.040 |
Why?
|
In Situ Hybridization | 1 | 1999 | 313 | 0.040 |
Why?
|
Interleukin-2 | 1 | 1999 | 241 | 0.040 |
Why?
|
Eosinophils | 1 | 1999 | 194 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2020 | 785 | 0.040 |
Why?
|
Cell Adhesion | 1 | 1999 | 426 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2012 | 2018 | 0.040 |
Why?
|
Keratosis | 1 | 1997 | 20 | 0.040 |
Why?
|
Basement Membrane | 1 | 2017 | 55 | 0.040 |
Why?
|
Interferon-gamma | 1 | 1999 | 449 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 359 | 0.030 |
Why?
|
Non-Fibrillar Collagens | 1 | 1996 | 3 | 0.030 |
Why?
|
Biopsy | 2 | 2017 | 1184 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 741 | 0.030 |
Why?
|
Fungemia | 1 | 2015 | 15 | 0.030 |
Why?
|
Insulin | 2 | 2014 | 1148 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 1996 | 228 | 0.030 |
Why?
|
Pilot Projects | 1 | 2018 | 872 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 1999 | 1801 | 0.030 |
Why?
|
Collagen | 1 | 1996 | 294 | 0.030 |
Why?
|
Muscle Strength | 1 | 2014 | 30 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2007 | 2370 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2014 | 64 | 0.030 |
Why?
|
Cells, Cultured | 1 | 1999 | 2887 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
|
Nerve Tissue Proteins | 1 | 1996 | 511 | 0.030 |
Why?
|
Carrier Proteins | 1 | 1996 | 679 | 0.030 |
Why?
|
Arterial Pressure | 1 | 2013 | 38 | 0.030 |
Why?
|
Urban Population | 1 | 2014 | 225 | 0.030 |
Why?
|
Lighting | 1 | 2012 | 33 | 0.030 |
Why?
|
Sleep, REM | 1 | 2012 | 51 | 0.030 |
Why?
|
North Carolina | 2 | 2003 | 51 | 0.030 |
Why?
|
Administration, Intravenous | 1 | 2012 | 56 | 0.030 |
Why?
|
Melatonin | 1 | 2012 | 50 | 0.030 |
Why?
|
Hospital Rapid Response Team | 1 | 2012 | 27 | 0.020 |
Why?
|
Resuscitation | 1 | 2013 | 111 | 0.020 |
Why?
|
Professional-Family Relations | 1 | 2012 | 54 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 151 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 95 | 0.020 |
Why?
|
Exercise | 1 | 2014 | 328 | 0.020 |
Why?
|
Hospitals, University | 1 | 2011 | 196 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 126 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2017 | 2770 | 0.020 |
Why?
|
Physician's Role | 1 | 2012 | 176 | 0.020 |
Why?
|
Blood Glucose | 1 | 2014 | 837 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1929 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 983 | 0.020 |
Why?
|
Iowa | 1 | 2009 | 35 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2009 | 19 | 0.020 |
Why?
|
Heart Rate | 1 | 2011 | 498 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 1606 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2009 | 205 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2011 | 1082 | 0.020 |
Why?
|
Blood Pressure | 1 | 2011 | 906 | 0.020 |
Why?
|
Survival Rate | 1 | 2011 | 1899 | 0.020 |
Why?
|
Age Factors | 1 | 2011 | 1880 | 0.020 |
Why?
|
Medical Staff | 1 | 2006 | 10 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 855 | 0.020 |
Why?
|
Blood Pressure Determination | 1 | 2006 | 60 | 0.020 |
Why?
|
Ultrasonography | 1 | 2009 | 720 | 0.020 |
Why?
|
Primary Health Care | 2 | 2002 | 352 | 0.020 |
Why?
|
Cognition | 1 | 2010 | 580 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 416 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2007 | 495 | 0.020 |
Why?
|
Anger | 1 | 2005 | 81 | 0.020 |
Why?
|
Arousal | 1 | 2005 | 170 | 0.020 |
Why?
|
Reference Values | 1 | 2005 | 662 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2005 | 295 | 0.010 |
Why?
|
Homeostasis | 1 | 2005 | 418 | 0.010 |
Why?
|
HLA Antigens | 2 | 1981 | 227 | 0.010 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2002 | 23 | 0.010 |
Why?
|
Hospitals, Veterans | 1 | 2002 | 21 | 0.010 |
Why?
|
Time and Motion Studies | 1 | 2002 | 21 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2007 | 2000 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1982 | 272 | 0.010 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1981 | 166 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 467 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 1766 | 0.010 |
Why?
|
Dystonin | 1 | 1996 | 3 | 0.010 |
Why?
|
Epitope Mapping | 1 | 1996 | 16 | 0.010 |
Why?
|
Immunoblotting | 1 | 1996 | 272 | 0.010 |
Why?
|
Japan | 1 | 1996 | 304 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 374 | 0.010 |
Why?
|
Observer Variation | 1 | 1997 | 614 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1996 | 563 | 0.010 |
Why?
|
Clinical Competence | 1 | 1997 | 797 | 0.010 |
Why?
|
Antigen-Antibody Complex | 2 | 1981 | 87 | 0.010 |
Why?
|
Complement System Proteins | 1 | 1980 | 82 | 0.000 |
Why?
|
Celiac Disease | 1 | 1980 | 214 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1981 | 1221 | 0.000 |
Why?
|